Molecular Profile Detail

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial	Phase	Therapies	Title	Recruitment Status	Covered Countries	Other Countries
NCT05469178	Phase Ib/II	Bemcentinib + Carboplatin + Pembrolizumab + Pemetrexed Disodium	A Clinical Study of Bemcentinib with Standard of Care Chemoimmunotherapy in Untreated Advanced/metastatic Non-small Cell Lung Cancer Patients with a Mutation in the STK11 Gene	Terminated	USA \| POL \| ITA \| HUN \| GRC \| FRA \| ESP	0
NCT06008093	Phase III	Cisplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Durvalumab + Pemetrexed Disodium + Tremelimumab Carboplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Durvalumab + Pemetrexed Disodium + Tremelimumab	A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients (TRITON)	Recruiting	USA	0
NCT01396408	Phase II	Temsirolimus Sunitinib	A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours	Active, not recruiting	CAN	0
NCT04512430	Phase II	Atezolizumab + Bevacizumab + Carboplatin + Pemetrexed Disodium	Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients	Terminated	ESP	0
NCT06495125	Phase II	Defactinib + Nivolumab + RO5126766	Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer	Recruiting	USA	0
NCT04564157	Phase III	Carboplatin + Nivolumab + Paclitaxel Carboplatin + Paclitaxel	New Adjuvant Trial of Chemotherapy vs Chemo-immunotherapy (NADIM-ADJUVANT)	Active, not recruiting	ESP	0
NCT04774952	Phase I	RMC-5552	Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors	Completed	USA	0
NCT05887492	Phase Ib/II	Pembrolizumab + TNG260	Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors	Recruiting	USA	0
NCT03375307	Phase II	Olaparib	Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes	Recruiting	USA	0
NCT04916236	Phase I	LY3214996 + RMC-4630	Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS Mutant Cancers (SHERPA)	Terminated	NLD	0
NCT05807048	Phase II	Daratumumab and hyaluronidase-fihj	Daratumumab in STK11 Mutated NSCLC	Recruiting	USA	0
NCT05704634	Phase I	Cemiplimab + Sarilumab	A Phase Ib Study to Evaluate the Safety and Preliminary Efficacy of IL6-receptor Antibody Sarilumab in Combination With antiPD1 Antibody Cemiplimab for Patients With Non-small Cell Lung Cancer.	Active, not recruiting	USA	0
NCT06431633	Phase II	Zimberelimab Cisplatin Sacituzumab govitecan-hziy + Zimberelimab Carboplatin	Study of Treatment with Sacituzumab and Zimberelimab for Patients with Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free. (ARIAN)	Recruiting	ESP	0
NCT07247786	Phase II	Carboplatin + Durvalumab + Paclitaxel Carboplatin + Durvalumab + Fecal microbiota + Paclitaxel	Study for Evaluating the Safety and Feasibility of Fecal Microbiota Transplant in Stage II-III NSCLC Patients Using ICI Responders as Donors (MIGRANT) (MIGRANT)	Not yet recruiting	ESP	0
NCT06120075	Phase I	AB801 AB801 + Docetaxel AB801 + Docetaxel + Zimberelimab	A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies (ARC-27)	Recruiting	USA	0
NCT06188208	Phase I	Pembrolizumab + VVD-130850 VVD-130850	A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130850 in Participants With Advanced Solid and Hematologic Tumors	Active, not recruiting	USA \| ESP \| AUS	0
NCT04471415	Phase Ib/II	DRP-104 Atezolizumab + DRP-104	Study to Investigate DRP-104 in Adults With Advanced Solid Tumors	Terminated	USA \| ESP \| DEU	2
NCT02352844	Phase II	Everolimus	Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 Mutations	Completed	USA	0
NCT04776447	Phase II	Atezolizumab + Carboplatin + Paclitaxel	Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO) (APOLO)	Active, not recruiting	ESP	0
NCT07207395	Phase II	JBI-802 JBI-802 + Pembrolizumab	A Study of Orally Administered JBI-802 Alone or in Combination With Pembrolizumab for Patients With Non-small Cell Lung Cancer With an STK11 Mutation.	Recruiting	USA	0
NCT07017829	Phase II	GT103 + Pembrolizumab	GT103 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic STK11 Mutant Non-Small Cell Lung Cancer	Recruiting	USA	0
NCT07153445	Phase II	Atezolizumab + Carboplatin + Paclitaxel	Neoadjuvant Treatment With Atezolizumab and Atezolizumab as Maintenance for the Treatment of Stage III Non Small-Cell Lung Cancer (NSCLC) (ATHENEA)	Recruiting	ESP	0
NCT02646319	Phase I	Nab-rapamycin	Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations	Completed	USA	0
NCT03872427	Phase II	Telaglenastat	Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study	Active, not recruiting	USA	0

Profile Name	STK11 mutant
Gene Variant Detail	STK11 mutant (unknown)
Relevant Treatment Approaches

Molecular Profile Detail

Contact

Filtering

Sorting